Nanobiotix ( (NBTX) ) has issued an announcement.
Nanobiotix announced a business update and financial results for 2024, highlighting the progress of its global development program for JNJ-1900 (NBTXR3) in oncology, with significant advancements in head and neck and lung cancer treatments. The company’s financial strategy has strengthened its position, extending its cash runway to mid-2026, and it has launched the Curadigm platform to enhance drug design. Despite recognizing negative revenues due to a one-time accounting adjustment, Nanobiotix remains optimistic about its future impact, supported by new clinical data and strategic collaborations.
More about Nanobiotix
Nanobiotix is a late-clinical stage biotechnology company pioneering nanotherapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases. The company focuses on developing innovative solutions in oncology, particularly through its lead programs in head and neck cancer and lung cancer.
YTD Price Performance: 23.45%
Average Trading Volume: 13,985
Technical Sentiment Signal: Strong Buy
Current Market Cap: $167.9M
See more insights into NBTX stock on TipRanks’ Stock Analysis page.